Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
J Neuroinflammation ; 17(1): 29, 2020 Jan 21.
Article in English | MEDLINE | ID: mdl-31964387

ABSTRACT

BACKGROUND: Metabolic syndrome, the development of which is associated with high-caloric Western diet (HCD) intake, represent a risk factor for mild cognitive impairment (MCI) and dementia including Alzheimer's disease (AD) later in life. This study aimed to investigate the effect of diet-induced metabolic disturbances on white matter neuroinflammation and cognitive function in a transgenic (TG) Fischer 344 rat carrying a human ß-amyloid precursor protein (APP) gene with Swedish and Indiana mutations (APP21 TG), a model of pre-AD and MCI. METHODS: TG and wildtype (WT) rats received either a HCD with 40% kJ from fat supplemented with 20% corn syrup drink or a standard diet for 12 weeks. Body weight, caloric intake, and blood pressure were measured repeatedly. End-point changes in glucose and lipid metabolism were also assessed. Open field task was used for assessment of activity; Morris water maze was used to assess spatial learning and memory. Cerebral white matter microglia and astrocytes, hippocampal neurons, and neuronal synapses were examined using immunohistochemistry. RESULTS: Rats maintained on the HCD developed significant obesity, visceral adiposity, dyslipidemia, and hyperinsulinemia, but did not become hypertensive. Impaired glucose tolerance was observed only in WT rats on the HCD. Total microglia number, activated OX-6+ microglia, as well as GFAP+ astrocytes located predominantly in the white matter were greater in the APP21 TG rat model in comparison to WT rats. HCD-driven metabolic perturbations further exacerbated white matter microgliosis and microglia cell activation in the APP21 TG rats and led to detectable changes in spatial reference memory in the comorbid prodromal AD and metabolic syndrome group compared to WT control rats. Neuronal density in the CA1 subregion of the hippocampus was not different between the experimental groups. Synaptic density in the CA1 and CA3 hippocampal subregions was lower in the TG rats compared to WT rats; however, there was no additional effect of the co-morbidity on this measure. CONCLUSIONS: These results suggest that white matter neuroinflammation might be one of the possible processes of early interaction of metabolic syndrome with MCI and pre-AD and could be one of the early brain pathologies contributing to cognitive deficits observed in mild cognitive impairment and dementia, including AD cases.


Subject(s)
Brain/pathology , Cognitive Dysfunction/pathology , Inflammation/pathology , Metabolic Syndrome/complications , White Matter/pathology , Alzheimer Disease/etiology , Alzheimer Disease/pathology , Amyloid beta-Protein Precursor/genetics , Animals , Cognitive Dysfunction/etiology , Comorbidity , Diet, High-Fat/adverse effects , Disease Models, Animal , Humans , Inflammation/etiology , Prodromal Symptoms , Rats , Rats, Inbred F344 , Rats, Transgenic
2.
Sci Rep ; 7(1): 16135, 2017 11 23.
Article in English | MEDLINE | ID: mdl-29170521

ABSTRACT

Alterations in the long chain base of the sphingosine moiety of gangliosides have been shown to play a role in neurodevelopment and neurodegeneration. Indeed, the accumulation of d20:1 sphingosine has been referred to as a metabolic marker of aging in the brain, however, this remains to be shown in simple gangliosides GM2 and GM3. In this study, Matrix-assisted laser desorption/ionization Imaging Mass Spectrometry (MALDI IMS) was used to examine the neuroanatomical distribution of A-series gangliosides with either 18 or 20 carbon sphingosine chains (d18:1 or d20:1) in Fisher 344 rats across the lifespan. The ratio of d20:1/d18:1 species was determined across 11 regions of interest in the brain. Interestingly, a decrease in the d20:1/d18:1 ratio for GM2 and GM3 was observed during early development with the exception of the peri-ventricular corpus callosum, where an age-dependent increase was observed for ganglioside GM3. An age-dependent increase in d20:1 species was confirmed for complex gangliosides GM1 and GD1 with the most significant increase during early development and a high degree of anatomical heterogeneity during aging. The unique neuroanatomically-specific responses of d20:1 ganglioside abundance may lead to a better understanding of regional vulnerability to damage in the aging brain.


Subject(s)
Brain/diagnostic imaging , Brain/metabolism , Gangliosides/metabolism , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Aging , Animals , G(M1) Ganglioside/metabolism , G(M3) Ganglioside/metabolism , Rats
3.
Brain Pathol ; 25(5): 531-42, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25187042

ABSTRACT

Beta-amyloid (Aß) accumulation, neuroinflammation, basal forebrain cholinergic loss and hippocampal degeneration are well-described pathologies associated with Alzheimer's disease (AD). However, the role that age plays in the susceptibility of the brain to these AD pathologies and the relationships between them is still not well understood. This study investigated the age-related response to intracerebroventricular injection of Aß(25-35) in 3-, 6- and 9-month-old rats. Aß toxicity resulted in an age-related increase in cholinergic loss and microglial activation in the basal forebrain along with neuronal loss in the hippocampal CA3 subfield. Performance in the Morris water maze revealed impairments in long-term reference memory in 6-month-old Aß administered animals, which was not seen in 3-month-old animals. These results support a role of Aß administration in inducing age-dependent cholinergic loss and neuroinflammation, and additionally provide evidence for a more age-appropriate model of adult-onset Aß toxicity demonstrating pathological changes that reflect the early stages of AD pathogenesis including neuroinflammation, cholinergic loss and beginning stages of memory impairment.


Subject(s)
Aging/pathology , Alzheimer Disease/pathology , Basal Forebrain/pathology , Cholinergic Neurons/pathology , Encephalitis/pathology , Aging/drug effects , Alzheimer Disease/chemically induced , Amyloid beta-Peptides/administration & dosage , Amyloid beta-Peptides/toxicity , Animals , Basal Forebrain/drug effects , CA3 Region, Hippocampal/drug effects , CA3 Region, Hippocampal/pathology , Cholinergic Neurons/drug effects , Encephalitis/chemically induced , Injections, Intraventricular , Male , Maze Learning/drug effects , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...